^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SCRI-CAR19
i
Other names: SCRI-CAR19, SCRI-CAR19v1, Patient Derived CD19 specific CAR T cells also expressing an EGFRt
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Seattle Children's Hospital
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
1year
A Phase 2 Trial of SCRI-CAR19 Demonstrates Favorable Leukemia-Free Survival (LFS), with a Pilot Study of CD19-Expressing T-Cell Antigen Presenting Cells (CD19t T-APCs) Demonstrating Safety and Tolerability (ASH 2023)
The primary efficacy cohort was defined as those who received fludarabine/cyclophosphamide (flu/cy) LD and were infused with CAR19. However, subjects were not randomized to receive T-APCs and those enrolled on PLAT-03 were more heavily treated and more likely to have received a prior HCT. Further exploration of T-APCs is warranted to define and evaluate their impact on persistence and durable responses.
Clinical • P2 data
|
CD19 (CD19 Molecule)
|
CD19 expression
|
cyclophosphamide • fludarabine IV • SCRI-CAR19
over2years
Modified manufacturing process modulates CD19CAR T-cell engraftment fitness and leukemia-free survival in pediatric and young adult subjects. (PubMed, Cancer Immunol Res)
We tested the modified manufacturing process and resulting product, designated SCRI-CAR19v2, in a cohort of 21 subjects on the phase 2 arm of the trial. Here, we describe the unanticipated enhancement in product performance resulting in prolonged persistence and B-cell aplasia, and improved leukemia-free survival with SCRI-CAR19v2 as compared to SCRI-CAR19v1.
Clinical Trial,Phase I • Journal • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
SCRI-CAR19
Share via
